CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy.
The efficient isolation and ex vivo expansion of antigen-specific T cells are crucial for successful adoptive immunotherapy against uncontrollable infections and cancers. Several methods have been reported for this purpose, for example, employing MHC-multimeric complexes, interferon-gamma secretion, and antibodies specific for molecules expressed on T-cell surfaces, including CD25, CD69, CD107a, CD137, and CD154. Of the latter, CD137 has been shown to be one of the most promising targets since it is only expressed on CD8(+) T cells early after encountering antigen, while being almost undetectable on resting cells. However, detailed comparisons between CD137-based and other methods have not yet been conducted. In this study, we therefore compared three approaches (with CD137, CD107a, and tetramers) using HLA-A24-restricted CMV pp65 and EBV BRLF1 epitopes as model antigens. We found that the CD137-based isolation of antigen-stimulated CD8(+) T cells was comparable to tetramer-based sorting in terms of purity and superior to the other two methods in terms of subsequent cell expansion. The method was less applicable to CD4(+) T cells since their CD137 upregulation is not sufficiently high. Collectively, this approach is most likely to be optimal among the methods tested for the isolation and expansion of antigen-specific CD8(+) cells.
Watanabe
Kazue
K
Research Reagent Division, Medical Biological Laboratories Co., Ltd., 1063-103 Ohara, Terasawaoka, Ina, Nagano, 396-0002, Japan. watanabe.kazue@mbl.co.jp.|Division of Immunology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan. watanabe.kazue@mbl.co.jp.
Suzuki
Susumu
S
T Cell Technologies, Inc., 3-5-10 Marunouchi, Naka-ku, Nagoya, 460-0002, Japan.
Kamei
Michi
M
Division of Immunology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.|Department of Pediatrics and Neonatology, Nagoya City University, Graduate School of Medical Science, Nagoya, Japan.
Toji
Shingo
S
Research Reagent Division, Medical Biological Laboratories Co., Ltd., 1063-103 Ohara, Terasawaoka, Ina, Nagano, 396-0002, Japan.
Kawase
Takakazu
T
Division of Immunology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.
Takahashi
Toshitada
T
Division of Immunology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.
Kuzushima
Kiyotaka
K
Division of Immunology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.|Department of Cellular Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Akatsuka
Yoshiki
Y
Division of Immunology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan. yakatsuk@aichi-cc.jp.
D019264:Adoptive Transfer; D000956:Antigens, Viral / Q000276:immunology / Q000494:pharmacology*; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology*; D018929:Cell Culture Techniques; D002469:Cell Separation; D002478:Cells, Cultured; D006801:Humans; D017874:Immediate-Early Proteins / Q000276:immunology / Q000494:pharmacology*; D010750:Phosphoproteins / Q000276:immunology / Q000494:pharmacology*; D015534:Trans-Activators / Q000276:immunology / Q000494:pharmacology*; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9; D014763:Viral Matrix Proteins / Q000276:immunology / Q000494:pharmacology*
D000956:Antigens, Viral; C068382:BRLF1 protein, Human herpesvirus 4; D017874:Immediate-Early Proteins; D010750:Phosphoproteins; D015534:Trans-Activators; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa